-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Carbidopa + Levodopa) in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Carbidopa + Levodopa) in Parkinson's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Carbidopa + Levodopa) in Parkinson's Disease Drug Details: The...
-
Product Insights
NewTardive Dyskinesia – Drugs In Development, 2024
Empower your strategies with our Tardive Dyskinesia – Drugs In Development, 2024 report and make more profitable business decisions. Tardive dyskinesia is a is a movement disorder characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts caused by the blockade of dopamine receptors. The Tardive Dyskinesia drugs in development market research report provide comprehensive information on the therapeutics under development for Tardive Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action...
-
Product Insights
NewLeukodystrophies – Drugs In Development, 2024
Empower your strategies with our Leukodystrophies – Drugs In Development, 2024 report and make more profitable business decisions. Leukodystrophies, a collection of rare genetic disorders impacting the central nervous system (CNS), specifically the brain and spinal cord, cause damage to the CNS's white matter. This damage hampers or obstructs signals between nerve cells, resulting in varied symptoms such as movement difficulties, vision and hearing impairment, and cognitive challenges. Due to the multitude of leukodystrophy types with differing symptoms, diagnosis poses a...
-
Product Insights
NewDyskinesia – Drugs In Development, 2024
Empower your strategies with our Dyskinesia – Drugs In Development, 2024 report and make more profitable business decisions. Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. The disease can be controlled by healthy life style and medication. The Dyskinesia drugs in development market research report provide comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by...
-
Product Insights
Contera Mgmt – Contera Park Ostrava D1 – Moravskoslezsky
Equip yourself with the essential tools needed to make informed and profitable decisions with our Contera Mgmt - Contera Park Ostrava D1 - Moravskoslezsky report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – JM-010
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry JM-010 Drug Details JM-010 (CTP-010) is under development for the treatment of levodopa-induced dyskinesia...
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movements. Its symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. However, the disease can be controlled by a healthy lifestyle and medication. The Dyskinesia pipeline market research report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...